Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Recent business development deals have focused on enhancing the company’s late-stage pipeline, including the company’s latest collaboration with Stoke Therapeutics. In parallel, Biogen’s ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Biogen faced several pipeline setbacks in 2024, including programs for ALS, tremor, and Angelman syndrome. Two promising late-stage programs, felzartamab entering Phase 3 trials for IgA ...

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t gotten the message yet. The Cambridge, Massachusetts ...

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in ...

The acquisition will expand Biogen’s rare disease pipeline by adding Hi-Bio’s lead candidate, felzartamab, a promising late-stage ready asset with potential application across a range of rare ...

Jefferies downgraded Biogen from Buy to Hold, setting a new price target of $180, down from $250. Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition.